New study tracks targeted drug zanubrutinib in rare blood cancer

NCT ID NCT05640102

Recruiting now Disease control Sponsor: BeiGene Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This study is tracking how well the drug zanubrutinib works and its safety in people with Waldenström macroglobulinemia, a rare blood cancer. Researchers are especially interested in patients with specific genetic mutations and those from racial and ethnic minority groups. The study will collect information from medical records and follow participants over time to see how they respond to treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zanubrutinib (a targeted cancer drug, also called Brukinsa)
What this could lead to: If successful, this study could confirm that zanubrutinib is effective and safe for a broader range of patients with Waldenström macroglobulinemia, including those from racial and ethnic minority groups.
What could go wrong: This is an observational study, not a controlled trial, so results may be less definitive. It is also relatively small (111 participants) and focuses on a rare blood cancer, so findings may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for WALDENSTROM MACROGLOBULINEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

WALDENSTROM MACROGLOBULINEMIA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

City of Hope National Medical Center
RECRUITING

Duarte, California, 91010-3012, United States
Clearview Cancer Institute
RECRUITING

Huntsville, Alabama, 35805-2606, United States
Comprehensive Cancer Centers of Nevada
RECRUITING

Las Vegas, Nevada, 89169-3321, United States
Eisenhower Medical Center, Lucy Curci Cancer Center
RECRUITING

Rancho Mirage, California, 92270-3221, United States
Hattiesburg Hematology and Oncology Clinic
ACTIVE_NOT_RECRUITING

Hattiesburg, Mississippi, 39401-7233, United States
Los Angeles Cancer Network (Lacn)
RECRUITING

Glendale, California, 91204-3640, United States
Pan American Oncology Trials, Llc
ACTIVE_NOT_RECRUITING

Rio Piedras, 00935, Puerto Rico
South Alabama Medical Science Foundation Mitchell Cancer Institute
RECRUITING

Mobile, Alabama, 36604-1405, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.